CLINDESSE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINDESSE (CLINDESSE).
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
| Metabolism | Primarily hepatic via CYP3A4-mediated metabolism to active and inactive metabolites. Clindamycin is a substrate of CYP3A4. |
| Excretion | Approximately 10% of a vaginal dose is absorbed systemically; absorbed drug is primarily metabolized in the liver, with about 85% of systemic clearance via biliary/fecal excretion and 15% via renal excretion as unchanged drug and metabolites. |
| Half-life | Following vaginal administration, the systemic half-life of clindamycin is approximately 2.5 hours, but local vaginal tissue levels persist for at least 24 hours due to sustained release from the formulation. |
| Protein binding | Clindamycin is 90-94% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Following systemic absorption, the apparent volume of distribution of clindamycin is approximately 0.6-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Systemic bioavailability after intravaginal administration is low (approximately 5-10%), with most of the dose remaining locally in the vagina. |
| Onset of Action | Clinical improvement in bacterial vaginosis symptoms is typically observed within 24-72 hours after the first vaginal application. |
| Duration of Action | A single vaginal dose (one applicatorful) provides local therapeutic effect for 24 hours; the full course of treatment is 7 consecutive days to ensure eradication of infection. |
One applicatorful (100 mg clindamycin phosphate) intravaginally once daily at bedtime for 3 consecutive days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dosage adjustment necessary in hepatic impairment; negligible systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients below 16 years have not been established; use not recommended. |
| Geriatric use | No specific geriatric dose adjustment; follow adult dosing. Clinical studies suggest similar efficacy and safety in older women. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINDESSE (CLINDESSE).
| Breastfeeding | Clindamycin is excreted into breast milk (M/P ratio approximately 0.6-1.1). Oral and parenteral clindamycin may cause gastrointestinal effects in nursing infants (diarrhea, bloody stools). Limited data for intravaginal clindamycin suggest minimal systemic absorption, likely negligible risk. Caution: monitor infant for diarrhea or thrush. Use only if clearly needed. |
| Teratogenic Risk | Clindamycin (CLINDESSE) is not associated with major teratogenic effects. Data from over 1000 exposed pregnancies do not indicate an increased risk of major congenital malformations. Second and third trimester exposure has not been linked to fetal adverse effects; however, use in the first trimester should be reserved for clear medical necessity. No known risk of abortifacient or fetotoxic effects. |
■ FDA Black Box Warning
None.
| Serious Effects |
["History of hypersensitivity to clindamycin, lincomycin, or any formulation components.","History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis."]
| Precautions | ["Clostridium difficile-associated diarrhea (CDAD) can occur, ranging from mild diarrhea to fatal colitis; consider discontinuation if diarrhea develops.","Hypersensitivity reactions including anaphylaxis and severe skin reactions (e.g., Stevens-Johnson syndrome) have been reported.","Overgrowth of non-susceptible organisms, including fungi, may occur with prolonged use.","Safety and efficacy in pediatric patients (<12 years) have not been established for the vaginal cream formulation."] |
| Food/Dietary | No specific food interactions. Avoid alcohol ingestion as it may cause disulfiram-like reaction with systemic clindamycin, but topical vaginal absorption is minimal. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. For prolonged use (e.g., >7 days), monitor maternal renal and hepatic function. Assess for signs of pseudomembranous colitis (diarrhea, abdominal pain). No routine obstetric ultrasound indicated solely due to clindamycin use. |
| Fertility Effects | No evidence of adverse effects on fertility in animal studies or human data. Vaginal clindamycin is not associated with impaired conception or reproductive outcomes. |
| Clinical Pearls | Clindesse (clindamycin phosphate) is a 2% vaginal cream for bacterial vaginosis. Single-dose application (5 g) at bedtime. Avoid concomitant use with other vaginal products. Not for use during menstruation; wait until menses ends. Efficacy similar to 7-day clindamycin regimens. May weaken latex condoms and diaphragms for up to 72 hours after use. |
| Patient Advice | Apply the full contents of one disposable applicator intravaginally at bedtime. · Do not use during your menstrual period; wait until it ends. · Avoid sexual intercourse or use of other vaginal products (tampons, douches) during treatment. · Latex condoms and diaphragms may be weakened; use alternative contraception for 72 hours after application. · Complete the single dose even if symptoms improve. · Contact your healthcare provider if symptoms persist or recur. |